Picture of Oehler
Associate Professor, Division of Hematology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center

Faculty Information


Dr. Oehler's research delves into the tyrosine kinase inhibitor imatinib mesylate (Gleevec), and now the second generation tyrosine kinase inhibitors dasatinib and nilotinib, which have dramatically altered treatment strategies in chronic myeloid leukemia (CML).  Outcomes for early (or chronic phase) disease are excellent.  However, a significant minority of chronic phase CML patients and many advanced CML patients develop resistance to therapy.  In the laboratory we are examining mechanisms involved in CML disease progression and the effects of tyrosine kinase inhibitor therapy on the underlying natural history of CML disease.  In the clinic we are pursuing phase one studies of new agents in the treatment of CML and AML.

CML provides a unique disease model in which to apply a translational approach.  Using microarray-based gene and microRNA expression studies of a large group of CML patients, we have identified expression changes in patients that are highly associated with disease progression and therapy resistance.   We are using these data to investigate several questions including:  can we identify candidates that predict which patients are at risk for early therapy failure or disease progression and can we determine how these genes and their targets cause disease progression and therapy resistance?  To answer the first question we are investigating a group of prognostic markers at diagnosis that can identify patients at risk for early disease progression or therapy failure.  Expression of these diagnostic mar

Education & Training: 
Harvard University
Cambridge, MA
Post-baccalaureate premed courses
New York
Case Western Reserve University School of Medicine
Clevland, OH
Internship, Internal Medicine
University of Washington Affiliated Hosptials
Seattle, WA
Residency, Internal Medicine
University of Washington Affiliated Hospitals
Seattle, WA
Hematology Fellowship
University of Washington Affiliated Hospitals
Seattle, WA
Post-Doctoral Research Fellow
Jerald Radich Laboratory, FHCRC
Seattle, WA
(206) 667-1340
Mailing Address: 

Fred Hutchinson Cancer Research Center
1100 Fairview Ave., N., D5-100
Seattle, WA 98109

Research & Clinical Interests
Research Interests: 

Mechanisms of leukemic disease progression and therapy resistance, new agents in the treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML)

Clinical Interests: 

Myeloproliferative and myelodysplastic disorders; acute myeloid leukemia